Copper More Critical than Lithium?
Lithium may have grabbed the headlines as a key material in building electric vehicles (EVs). But so is copper. And copper's importance in the new green economy goes far beyond EVs. Copper is critical in building wind turbines and solar panels. It's key to power lines and upgrading the national grid. Analysts say we're facing a 10-million-ton shortfall if new copper mines are not found.
See How To Can Benefit From New Copper Discoveries
Todd A. Trapp, insider at Abiomed

Todd A. Trapp Insider Information

CFO of Abiomed
Mr. Todd A. Trapp joined Abiomed in 2018 from Watts Water Technologies, Inc., a $1.5B global manufacturing leader of innovative products to control the efficiency, safety and quality of water within residential and commercial applications, where he served as CFO. Prior to joining Watts Water Technologies, Mr. Trapp spent 13 years in a variety of financial and operational roles at Honeywell International Inc., a $40B diversified technology and manufacturing company. At Honeywell, Mr. Trapp served as vice president of financial planning and analysis, chief financial officer of the airlines business unit, director of finance for the transportation systems division, investor relations manager and other senior finance positions. Prior to joining Honeywell, Mr. Trapp held several treasury and finance operational roles at United Business Media, Inc. and Pearson, Inc. Mr. Trapp holds a Bachelor of Science in accounting from Providence College and a Master of Business Administration in finance from Northeastern University.

What is Todd A. Trapp's net worth?

The estimated net worth of Todd A. Trapp is at least $4.77 million as of August 3rd, 2022. Mr. Trapp owns 16,927 shares of Abiomed stock worth more than $4,768,505 as of August 10th. This net worth estimate does not reflect any other assets that Mr. Trapp may own. Additionally, Mr. Trapp receives an annual salary of $914,930.00 as CFO at Abiomed. Learn More about Todd A. Trapp's net worth.

How old is Todd A. Trapp?

Mr. Trapp is currently 51 years old. There are 6 older executives and no younger executives at Abiomed. The oldest executive at Abiomed is Dr. David M. Weber Ph.D., Scientific & Technology Advisor, who is 61 years old. Learn More on Todd A. Trapp's age.

What is Todd A. Trapp's salary?

As the CFO of Abiomed, Inc., Mr. Trapp earned a total compensation package of $4,766,734.00 in 2021. Mr. Trapp earned a salary of $430,000.00, stock awards of $3,496,819.00, options awards of $503,189.00, non-equity compensation of $327,600.00, and other compensation of $9,126.00.There are 2 executives that earn more than Mr. Trapp. The highest earning executive at Abiomed is Mr. Michael R. Minogue, Chairman, CEO & Pres, who commands a salary of $3,040,000.00 per year. Learn More on Todd A. Trapp's salary.

How do I contact Todd A. Trapp?

The corporate mailing address for Mr. Trapp and other Abiomed executives is 22 CHERRY HILL DR, DANVERS MA, 01923. Abiomed can also be reached via phone at (978) 646-1400 and via email at [email protected] Learn More on Todd A. Trapp's contact information.

Has Todd A. Trapp been buying or selling shares of Abiomed?

During the last quarter, Todd A. Trapp has sold $300,000.00 in shares of Abiomed stock. Most recently, Todd A. Trapp sold 1,000 shares of the business's stock in a transaction on Wednesday, August 3rd. The shares were sold at an average price of $300.00, for a transaction totalling $300,000.00. Following the completion of the sale, the chief financial officer now directly owns 16,927 shares of the company's stock, valued at $5,078,100. Learn More on Todd A. Trapp's trading history.

Who are Abiomed's active insiders?

Abiomed's insider roster includes Andrew Greenfield (VP), Michael Minogue (CEO), Michael Minogue (CEO), Dorothy Puhy (Director), Joseph Riccelli, Sr. (CEO), Martin Sutter (Director), Paul Thomas (Director), Todd Trapp (CFO), David Weber (COO), and Magdalena Yesil (Director). Learn More on Abiomed's active insiders.

Are insiders buying or selling shares of Abiomed?

In the last twelve months, insiders at the medical equipment provider sold shares 13 times. They sold a total of 44,817 shares worth more than $14,819,764.29. The most recent insider tranaction occured on August, 3rd when CFO Todd A Trapp sold 1,000 shares worth more than $300,000.00. Insiders at Abiomed own 2.5 % of the company. Learn More about insider trades at Abiomed.

Information on this page was last updated on 8/3/2022.

Todd A. Trapp Insider Trading History at Abiomed

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/3/2022Sell1,000$300.00$300,000.0016,927View SEC Filing Icon  
4/4/2022Sell1,000$333.00$333,000.0013,063View SEC Filing Icon  
1/5/2022Sell1,000$359.43$359,430.00View SEC Filing Icon  
See Full Table

Todd A. Trapp Buying and Selling Activity at Abiomed

This chart shows Todd A Trapp's buying and selling at Abiomed by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Abiomed Company Overview

Abiomed logo
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
Read More

Today's Range

Now: $293.25
Low: $288.06
High: $293.25

50 Day Range

MA: $263.24
Low: $224.73
High: $301.46

2 Week Range

Now: $293.25
Low: $219.85
High: $379.30

Volume

4,738 shs

Average Volume

333,751 shs

Market Capitalization

$13.38 billion

P/E Ratio

61.87

Dividend Yield

N/A

Beta

1.35
Copper More Critical than Lithium?
Lithium may have grabbed the headlines as a key material in building electric vehicles (EVs). But so is copper. And copper's importance in the new green economy goes far beyond EVs. Copper is critical in building wind turbines and solar panels. It's key to power lines and upgrading the national grid. Analysts say we're facing a 10-million-ton shortfall if new copper mines are not found.
See How To Can Benefit From New Copper Discoveries